Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa
2021-07-15 10:00
Johnson & Johnson Innovation announces extension of innovation partnering office at Monash University in collaboration with Victorian State Government to accelerate the life-sciences hub
2021-07-15 10:00
Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of Lisaftoclax (APG-2575) and Equity Investment
2021-07-15 01:43
Innovent and Ascentage Pharma Reach Multifaceted Strategic Agreement including Joint Commercialization of Olverembatinib in China, Joint Clinical Development on Multiple Products, and Equity Investment
2021-07-14 23:48
Nippon Express Italia Acquires GDP Certification for Company-owned Warehouse near Milan Malpensa Airport
2021-07-14 15:00
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne
2021-07-14 07:05
Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus
2021-07-13 20:00
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China
2021-07-13 19:47
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China
2021-07-13 08:30
Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
2021-07-12 23:00
Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies
2021-07-12 17:00
Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem(TM) into clinic
2021-07-12 14:00
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent
2021-07-12 12:42
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors
2021-07-12 08:12
Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US
2021-07-11 21:03
Clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
2021-07-09 21:38
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
2021-07-09 20:00
Sequanta and Mission Bio announce strategic partnership
2021-07-09 15:44
Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement
2021-07-09 08:00
COVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them
2021-07-08 16:00
1
234
235
236
237
238
413